Roche's PATHWAY HER2 Test Gains FDA Approval for Biliary Tract Cancer Patients Roche’s PATHWAY HER2 (4B5) test is now FDA-approved to identify biliary tract cancer patients eligible for HER2-targeted ZIIHERA treatment, improving care options.

Roche's PATHWAY HER2 Test Gains FDA Approval for Biliary Tract Cancer Patients #USA #Roche #ZIIHERA #PATHWAY_HER2 #Tucson